510(k) device
UroLift Advanced Tissue Control (ATC) System
Neotract, Inc. · Implantable Transprostatic Tissue Retractor System (PEW, Class II) · First FDA decision Jun 5, 2020, newest Jun 5, 2020Enlarged prostate (BPH)
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
1
510(k) pathway
Device trials
1
Naming "UroLift Advanced"
MAUDE reports
1
Brand "UroLift Advanced", since 2015
PubMed studies
0
Mentioning "UroLift Advanced"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing UroLift Advanced Tissue Control (ATC) System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 1 of 1 decisions filed under this name.
K200441 · Decided Jun 5, 2020 · 102 days after receipt
Device type: Implantable Transprostatic Tissue Retractor System (PEW) · GI, Urology & Nephrology
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "UroLift Advanced", any status and sponsor, newest update first.
St. Louis UniversityAcademic, hospital or other
NCT03043222 · 0 participants · Start Mar 1, 2018 · Primary completion Apr 1, 2019
Device: UroLift as artifical device for prostatic urethral lift.; Embospheres Microspheres as embolic agents for prostate artery embolization · For: Lower Urinary Tract Symptoms; Benign Prostatic Hyperplasia; Urinary Frequency/Urgency and 3 more
Sites: St Louis, Missouri
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "UroLift Advanced", and for the whole product code for context.
This brand
1 reports: 1 malfunction, 0 injury, 0 death
Whole product code PEW
498 reports: 250 malfunction, 236 injury, 12 death
Newest reports for this brand
3005791775-2020-00046 · Received Oct 2, 2020 · Event dated Aug 17, 2020
Device type: Implantable Transprostatic Tissue Retractor System (PEW)
Device problem as coded: Fracture
Patient problem as coded: No Known Impact Or Consequence To Patient
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "UroLift Advanced"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code PEW.
- UroLift System (UL400)Neotract, Inc. · De Novo 2019
- NeoTract UroLift System UL500Neotract, Inc. · 510(k) 2016
- UroLift 2 ATC Advanced Tissue Control SystemNeotract, Inc. · 510(k) 2023
- UroLift 2 System (formerly UL500)Neotract, Inc. · 510(k) 2020
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.